Physician's Weekly10d
PD-1/PD-L1 Inhibitors With Chemotherapy vs. Platinum-Based Treatment in Advanced Urothelial Cancer
The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...
Fierce Pharma1d
FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again
Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...
BioSpace3d
GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors
The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...
The Scientist9y
PD-1 Inhibitor Screening Assay Kit
AMSBIO has announced a new PD-1 (Programmed Death) inhibitor screening assay kit for cancer research studies. Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally ...
BioWorld26d
Ilab patents new PD-1/PD-L1 interaction inhibitors
Ilab Co. Ltd. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer.
pharmaphorum5d
Blow for Novartis as PD-1 drug spartalizumab flunks trial
The company has mid-stage trials of the PD-1 inhibitor on the go as a combination therapy with CSF-1 inhibitor BLZ945 in solid tumours, c-Met inhibitor capmatinib in liver cancer, and Palobiofarma ...